

An Increase in Dietary n-3 Fatty Acids Decreases a Marker of Bone Resorption in Humans

Amy E. Griel PhD^{1,2}, Penny M. Kris-Etherton PhD, RD^{1,2},
Kirsten F. Hilpert PhD^{1,2}, Guixiang Zhao PhD¹, Sheila G. West PhD³, Rebecca L.
Corwin, PhD, RD^{1,2}

¹Department of Nutritional Sciences, ²The Huck Institutes of the Life Sciences,
³Department of Biobehavioral Health, The Pennsylvania State University, University
Park, PA, 16802 USA

¹Department of Nutritional Sciences
126 S Henderson Bldg

²The Huck Institutes of the Life Sciences
201 Life Sciences Bldg

³Department of Biobehavioral Health
315 Health & Human Development East
The Pennsylvania State University
University Park, PA 16802
USA

Running Title: Dietary ALA Decreases NTx

Key words: polyunsaturated fatty acids, n-3 fatty acids, walnuts, bone resorption, bone formation, humans

Corresponding Authors

Rebecca L. Corwin PhD, RD
Department of Nutritional Sciences
126 S Henderson Bldg.
The Pennsylvania State University
University Park, PA 16802
rxc13@psu.edu
(814) 865-6519
(814) 863-6103 FAX

Amy E. Griel, PhD
Department of Nutritional Sciences
126 S Henderson Bldg.
The Pennsylvania State University
University Park, PA 16802
aeg126@psu.edu
(814) 863-8056
(814) 863-6026 FAX

Abstract

Human, animal, and in vitro research indicates a beneficial effect of appropriate amounts of omega-3 (n-3) polyunsaturated fatty acids (PUFA) on bone health. This is the first controlled feeding study in humans to evaluate the effect of dietary plant-derived n-3 PUFA on bone turnover, assessed by serum concentrations of N-telopeptides (NTx) and bone-specific alkaline phosphatase (BSAP). Subjects (n=23) consumed each diet for 6 weeks in a randomized, 3-period crossover design: 1) Average American Diet (AAD; [34% total fat, 13% saturated fatty acids (SFA), 13% monounsaturated fatty acids (MUFA), 9% PUFA (7.7% LA, 0.8% ALA)]), 2) Linoleic Acid Diet (LA; [37% total fat, 9% SFA, 12% MUFA, 16% PUFA (12.6% LA, 3.6% ALA)]), and 3) α -Linolenic Acid Diet (ALA; [38% total fat, 8% SFA, 12% MUFA, 17% PUFA (10.5% LA, 6.5% ALA)]). Walnuts and flaxseed oil were the predominant sources of ALA. NTx levels were significantly lower following the ALA diet (13.20 ± 1.21 nM BCE), relative to the AAD (15.59 ± 1.21 nM BCE) ($p < 0.05$). Mean NTx level following the LA diet was 13.80 ± 1.21 nM BCE. There was no change in levels of BSAP across the three diets. Concentrations of NTx were positively correlated with the pro-inflammatory cytokine TNF α for all three diets. The results indicate that plant sources of dietary n-3 PUFA may have a protective effect on bone metabolism via a decrease in bone resorption in the presence of consistent levels of bone formation.

Introduction

Accumulating evidence indicates that dietary fats can influence bone health. The omega-3 (n-3) polyunsaturated fatty acids (PUFA), in particular, may be beneficial, as they have been shown to inhibit the activity of osteoclasts and enhance the activity of osteoblasts in animals [1, 2]. Optimal quantities of n-3 PUFA, thus, appear to inhibit bone resorption and promote bone formation. In addition, the ratio of n-6 to n-3 fatty acids in the diet may be important. Lowering the dietary ratio of n-6/n-3 PUFA increased bone marrow cellularity [3] and bone strength [4] in animals. In contrast, other studies have indicated that dietary saturated fatty acids (SFA) may adversely affect bone health. Animal research [5] and epidemiologic data [6] indicate that diets rich in SFA reduce bone mineral density. Possible mechanisms that may account for the effects of dietary fatty acids on bone include alterations in prostaglandin production, lipid oxidation, calcium absorption, inflammatory processes and osteoblast differentiation [2, 7-11].

Few studies have evaluated the relationship between dietary fats and bone status in humans. Epidemiological studies have shown inverse relationships between the dietary n-6/n-3 ratio and bone mineral density in older adults [12], as well as between dietary saturated fat and bone mineral density in men [6]. In contrast, a tendency toward a positive relationship between eicosapentaenoic acid (EPA; n-3) consumption and bone density has been reported [13]. Supplementation trials also indicate positive effects of n-3 fatty acids on bone health. Twelve months of EPA supplementation, for instance, increased a measure of bone density in postmenopausal women [13]. Other studies [14, 15] provided oil supplements containing γ -linolenic acid (GLA) (n-6), EPA and docosahexanoic acid (DHA) (n-3) to women. When these supplements were consumed

for 16 weeks serum markers indicative of bone formation increased [16]. When consumed for longer periods of time, the results were mixed in that n-3/GLA supplementation increased bone density, compared to a placebo containing SFA in one study [14]; however, in the other study, there was no n-3/GLA benefit compared to no supplemental fat [15]. It is likely that the lack of effect observed by Bassey et al. [15] was due to the large measurement error associated with total body bone mineral density measurements and the shorter study period (12 vs. 18 mos.). In contrast, the study design employed by Kruger et al [14] used more specific measures of bone density (spine and hip bone mineral density scans) to quantify changes over time.

A lack of effect of n-3 fatty acids on bone health also has been reported. In a recent study of 179 menopausal women no change in bone mineral density was observed following supplementation of 40g flaxseed/d (9.1 g α -linolenic acid; ALA) for 12 months [17]. Similarly, in a randomized controlled trial of chronically inflamed (elevated levels of c-reactive protein) patients with Crohn's disease, supplementation of 2.7 g/d of EPA and DHA and antioxidants (vitamins A, C and E and selenium) elicited no changes in markers of bone resorption and bone formation, despite a significant increase in plasma levels of EPA, DHA and selenium [18]. Taken together, the epidemiologic and supplemental feeding data provide some suggestive evidence that dietary fatty acids, specifically n-3 fatty acids, can affect bone health in humans. By design, supplement studies typically do not involve control of the background diet, and it is possible that differences across studies could be explained by failure to control for other nutrients that affect bone. Therefore, controlled feeding trials are needed in order to convincingly demonstrate a causal relationship between fatty acids and bone health. Whereas there are

some positive data with marine-derived n-3 fatty acids, there is little known about the role of plant-based n-3 fatty acids (ALA) in bone health.

The present investigation is the first controlled feeding study in humans to evaluate the effect of increasing dietary ALA and, thereby, decreasing the ratio of n-6/n-3 PUFA on bone health. Plant sources of ALA (walnuts and flax) were used. We recently showed that an ALA-rich diet inhibits vascular inflammation and endothelial activation in addition to having substantial lipid lowering effects [19]. A growing body of evidence indicates that many of the pathophysiological events associated with CVD also are associated with low bone density. Given the literature indicating effects of dietary fatty acids on bone health, as well as reported associations between cardiovascular disease and low bone density/osteoporosis [20], we sought to determine if plant-based n-3 PUFA also would be beneficial to bone health.

Subjects and Methods

Subjects

The present study was part of a larger study [19] that was designed to evaluate the effects of dietary fatty acids on cardiovascular disease risk factors. All twenty-three individuals (20 males and 3 females) participated in both studies. Subjects were recruited via advertisements in the local newspaper and fliers distributed across the campus of the Pennsylvania State University. Subjects who met the initial criteria during a phone screen reported to the Metabolic Diet Study Center (MDSC) for anthropometric measurements and baseline blood sampling. The Institutional Review Board at the Pennsylvania State University approved the experimental protocol and all subjects provided written informed consent.

Baseline subject characteristics are shown in Table 1. Subjects were classified as overweight or obese, i.e., BMI between 25 and 35 kg/m². In addition, subjects were moderately hypercholesterolemic [baseline serum total cholesterol (TC) between 5.17 and 6.21 mmol/L, LDL-cholesterol (LDL-C) between 40th and 90th percentiles (by NHANES III), with HDL-cholesterol (HDL-C) between 25th and 75th percentiles (by NHANES III)], and had serum triglyceride (TG) levels less than 3.95 mmol/L. Thus, subjects in the present study were quite representative of the population in the U.S. that is at high risk for cardiovascular disease. The three females were postmenopausal, and had not received hormone replacement therapy (HRT) for at least 6 months prior to the start of the study.

Study Design

A randomized, double-blind, balanced order, three-period crossover design was employed. A Latin-Square protocol was used to randomize the subjects into a sequence of three experimental diets, which differed in their fatty acid composition. Diet periods lasted 6 weeks and were separated by an approximate 3-week compliance break during which subjects consumed their usual diet. The period of time that subjects consumed the diets (6 weeks) exceeded that for which alterations in serum NTx and BSAP have been reported in other studies [21, 22].

Subjects consumed either breakfast or dinner at the diet center on Monday through Friday; all other meals were prepared and packed for offsite consumption at the subjects' home. Diet compliance was monitored by the staff of the diet center and by the review of daily and weekly monitoring forms. Subjects' body weights, usual activities and exercise levels were maintained throughout the course of the study.

Experimental Diets

Three test diets were used: an average American diet (AAD) that served as the control diet, and two high-PUFA diets (low in saturated fat and cholesterol) that had different amounts of linoleic acid [LA, C18:2 n-6, (LA Diet)] and α -linolenic acid [ALA, C18:3 n-3 (ALA Diet)]. For each of the three experimental diets, eight calorie levels (1800 - 3900 kcal) were developed to meet different energy needs of the subjects. Unit foods (muffins) containing the same macronutrient profile of each of the test diets were used during each diet period to provide incremental adjustments of 100 kcal/day as needed to maintain body weight. The nutrient composition of the three test diets, verified by chemical analyses, is reported in Table 2. All diets were nutritionally adequate and met 2/3 of the established Dietary Reference Intakes [23]. In addition, each of the three test diets met or exceeded dietary recommendations for both ALA and LA [24]. Total fat (~35% energy), carbohydrate (~50% energy) and protein (~15% energy) were kept as constant as possible across the three experimental diets. There were no differences across the 3 diets for calcium and vitamin D.

The ratio of n-6/n-3 fatty acids for the LA and ALA diets were 3.5/1 and 1.6/1, respectively. The n-6/n-3 fatty acid ratio for the AAD was 9/1. The ratios differed primarily because of a marked increase in ALA in the LA and ALA diets; the quantity of LA was high for both of these diets although it was slightly lower on the ALA diet. Walnuts and walnut oil, which are particularly rich sources of both n-6 and n-3 PUFA, represented half of the total fat in the two high-PUFA diets. The daily consumption of walnuts and walnut oil was 37 g and 15 g, respectively, for the diet providing 2400 kcal/day. Sources of walnuts in the diet included walnut granola, honey walnut butter,

walnut pesto, and plain walnuts as a snack. Flaxseed oil, ~20 g/day for the 2400 kcal/day diet, also was used to increase the ALA content of the ALA Diet. Dietary calcium and Vitamin D levels were calculated using the Nutritionist V database (N-Squared Computing, First DataBank Division, San Bruno, CA).

Serum Samples

Twelve hour fasting blood samples were taken by venipuncture on two consecutive days. Whole blood was centrifuged at 3000 rpm for 15 minutes at 4°C. Serum samples were aliquoted and stored at -80°C until the conclusion of the study when all samples were analyzed together. The serum fatty acid profile was determined using gas chromatography as described by Zhao et al [19]. In short, serum total lipids were extracted using a chloroform:methanol mixture (1:1, v:v) containing BHT (Sigma) and heptadecanoic acid (used as an internal standard, Nu-Chek-Prep); serum fatty acid composition was determined using gas chromatography. Percentage of individual fatty acids was calculated according to the peak areas relative to the total area (total fatty acid was set at 100%). Serum N-telopeptides of type I collagen (NTx) were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Ostex International, Seattle); the intra-assay coefficient of variation was 5.5%. Serum NTx is regarded as a reliable indicator of bone resorption since it originates from proteolytic cleavage of bone collagen by osteoclasts, rather than by downstream degradative processes [25]. Furthermore, measures of serum NTx exhibit less individual variability than do those of urine [26, 27]. Serum bone-specific alkaline phosphatase (BSAP) was determined using a chemiluminescent enzymatic assay (Quest Diagnostics, Chantilly, VA). BSAP provides a general index of bone formation, and a specific index of total osteoblast

activity [28]. Serum TNF- α , IL-6, IL-4 and IL-1 β levels were measured using ELISAs in the Cytokine Core Laboratory of the Pennsylvania State University General Clinical Research Center using protocols previously described [29].

Statistical Analyses

All statistical analyses were performed using SAS for WINDOWS, release 8.2 (SAS Institute, Cary, NC). Data are expressed as least squares mean \pm standard error. Normality testing was conducted for each outcome variable. The Kolmogorov-Smirnov test was used to identify 2 individuals whose NTx levels fell outside of the normal distribution and were classified as outliers. The mixed models procedure (PROC MIXED) was used to test for effects of diet, order of diet presentation, period, and their interactions. Tukey-Kramer adjusted *P* values < 0.05 were used to determine whether the differences in NTx among diets were significant. The magnitude and direction of diet effects were also examined by analyzing change scores (experimental diets – AAD), with AAD values as covariates. Pearson correlation coefficients were used to evaluate the relationship between the levels of NTx and the log-transformed levels of TNF α , IL-6, IL-4, and IL-1 β across all diets. In order to account for the repeated measurement of outcome variables across three diet periods, an average correlation for each diet was calculated and the significance of this pooled correlation was then tested using a repeated measures ANOVA with the subject variable as the repeated measure. All analyses were performed on log-transformed values; all means reported represent unadjusted means.

Results

All subjects completed the study (Table 1) and serum fatty acid analysis (Table 3) revealed excellent dietary compliance [19]. Statistical analyses were first completed with all subjects (n=23) and then on all male subjects (n=20). Both sets of analyses yielded similar results, thus men and women were pooled for all analyses presented. Subjects maintained their baseline body weight throughout the study. NTx values for one male and one female subject were classified as significant outliers and excluded from the analyses, based on the Kolmogorov-Smirnov test. The final sample size was 21.

Mean NTx concentrations (\pm SE) at the conclusion of the three experimental diets were 15.59 ± 1.21 , 13.80 ± 1.21 , and 13.20 ± 1.21 nM BCE, for the AAD, LA and ALA diets, respectively (main effect of diet: $p < 0.05$). NTx levels were significantly lower following the ALA diet ($p < 0.05$) and there was a similar trend for the LA diet ($p = 0.08$), compared to the AAD diet (Figure 1). When change scores were analyzed with the control diet (AAD) NTx levels as a covariate, both the ALA and LA diets were associated with significant reductions in NTX concentrations ($p < 0.05$) relative to the AAD. The reduction following the ALA diet was 2.17 ± 0.68 nM BCE (15.3%), while the reduction following the LA diet was 1.77 ± 0.68 nM BCE (11.5%).

Levels of BSAP were unaffected by diet treatment. Mean concentrations of BSAP at the end of each diet period were 11.78 ± 0.80 , 12.41 ± 0.80 , and 11.94 ± 0.81 mcg/L, for the AAD, LA and ALA diets, respectively ($p > 0.05$). Similarly, the analysis of change scores adjusted for control diet BSAP showed no significant effects of the intervention diets.

The effects of these diets on serum cytokine levels are reported elsewhere [30]. In summary, levels of IL-6, IL-1 β and IL-4 did not change after consumption of the three test diets. Levels of serum TNF α however were reduced following the ALA Diet (Median: 10.3 ng/L; Range: (1.2-12,072.7 ng/L), compared to the LA Diet (Median: 13.3 ng/L; Range: (1.2-1,513.0 ng/L) and the AAD (Median: 18.2 ng/L; Range: (1.2-1,232.5 ng/L) (main effect of diet: $p < 0.08$). In subsequent correlational analysis, data from the 16 individuals with detectable levels of TNF α were used. The levels of NTx were positively correlated with the levels of TNF- α ($r = 0.54$; $p < 0.05$), across all three diets. Thus, as TNF- α decreased with increasing intake of n-3 fatty acids, there were proportional decreases in NTx.

Effects of diet on serum fatty acids

The serum fatty acid profile for subjects following the consumption of each of the three test diets is presented in Table 3. The changes observed in serum fatty acids validate our assessment of dietary compliance with daily and weekly monitoring forms. As expected, serum total n-6 PUFA were the highest on the LA diet ($p < 0.001$). Serum total n-3 PUFA, ALA, and EPA increased progressively across the LA and ALA diets, with the highest levels on the ALA diet. The ratios of serum SFA:UNSAT, LA:ALA and n-6/n-3 decreased significantly following the consumption of the LA and ALA diets, compared to the AAD ($p < 0.001$), and following consumption of the ALA diet compared to the LA diet ($p < 0.001$). There were no significant correlations between serum concentrations of fatty acids and BSAP or NTx.

Discussion

This is the first controlled feeding study in humans to assess the effects of diets rich in ALA and LA provided by walnuts and flaxseed on bone health, as measured by serum NTx and BSAP, indicators of bone resorption and formation, respectively. We found that the high PUFA diets reduced serum concentrations of NTx, and maintained levels of BSAP relative to the consumption of a typical American diet, which is lower in PUFA and higher in SFA. NTx after consumption of the ALA diet in particular, was significantly lower than was NTx after consumption of the AAD. These effects are consistent with a reduction in bone turnover and maintenance of bone formation induced by relatively short-term consumption of the high PUFA diets. Although the effects of dietary fats on bone health have been studied in animals and through supplementation in humans, this is the first study to use a whole food source, incorporated into the diet of humans under controlled feeding conditions. Previous studies have shown beneficial effects of walnuts [19, 31] and flaxseed [32] on CVD risk; the present results indicate potential benefits on bone health, as well.

Some scientists believe that the ratio of dietary n-6/n-3 PUFA is important to a variety of health outcomes [33]. The changes in n-6/n-3 ratios in the present study were accomplished by increasing the n-3 PUFA, while maintaining relatively constant levels of n-6 PUFA (Table 2). NTx levels were significantly lower when subjects consumed the ALA diet (n-6/n-3 ratio: 1.6) than when they consumed the AAD (n-6/n-3 ratio: 9.5); when subjects consumed the LA diet (n-6/n-3 ratio: 3.5), NTx levels were marginally significantly lower than when they consumed the AAD ($p=0.08$). This stepwise reduction in NTx across the three diets (ALA < LA < AAD) indicates a possible dose-

response effect of dietary n-3 fatty acids and/or reductions in the n-6/n-3 ratio on bone resorption. The stepwise nature of the results also indicates that the reductions in NTx were not due simply to the lower dietary SFA or the elevated LA in the LA and ALA diets.

The present results do not clearly distinguish if the observed effects are due to the ALA or to the conversion of ALA to EPA and its subsequent effects. The majority of studies investigating the effects of n-3 fatty acids on bone health have used fish oil, which is rich in EPA. However, a recent epidemiologic study showed that reduced LA/ALA ratios were associated with increased hip bone mineral density [12]. In the present study, plant sources of n-3 fatty acids were used; therefore, ALA was the primary n-3 fatty acid provided by the diet. In addition, the amount of ALA in the ALA diet (~17 g/day on the 2400 kcal diet) was greater than that previously provided in a supplementation trial (~9 g/day) [17]. Both serum ALA and EPA were significantly greater in the LA and ALA diet conditions than in the AAD condition. However, serum ALA increased to a greater degree than did EPA, which reflects the well established fact that little ALA is converted to EPA (~ 5-10%), and little is converted to DHA (< 1%) [34, 35]. In the presence of a diet that is relatively high in n-6 PUFA (such as the LA and ALA diets in the present study), this conversion is reduced by 40 to 50% [36]. Therefore, it is possible that in the present study the results are reflective of an increase in ALA or due to potent effects of EPA. Further research is needed to clarify these possibilities.

The reduction in serum NTx that occurred in the present study following the consumption of the ALA diet for 6 weeks (15.3%) is somewhat less than reports after two weeks and 1 year of hormone replacement therapy (23% and 52%, respectively) or after 6

months of alendronate therapy (30.4%) [37, 38]. Whether longer-term intake of n-3 PUFA would produce larger decreases in NTx and/or increases in bone density is not known. Regardless, the present findings confirm and extend a growing literature indicating beneficial effects of n-3 PUFA and reduced n-6/n-3 ratios on bone health.

The present results are consistent with animal work in which appropriate amounts of n-3 PUFA reduced osteoclast activity [1]. One mechanism that might account for this involves local alterations of fatty acid and prostaglandin concentrations within bone tissue [8]. Increased consumption of n-6 PUFA increases the ratio of arachidonic acid (AA) to EPA, and increases PGE₂ concentration in bone [28]. Conversely, an increased consumption of n-3 PUFA decreases the AA:EPA ratio, and decreases PGE₂ concentration and release from bone. This cascade of effects is potentially important, as PGE₂ has been reported to stimulate bone resorption [see 10 for review]. EPA serves as a precursor for the formation of PGE₃, which also can stimulate bone resorption. However, the conversion of EPA to PGE₃ is much less efficient than is the conversion of AA to PGE₂ [39]. Although measurements of bone prostaglandins were not taken in the present study, the serum fatty acid results showed that serum EPA was significantly greater on the ALA diet than on either the LA diet or the AAD [19], while AA was significantly reduced. It is possible that this shift in fatty acid synthesis decreased production of PGE₂ within the bone while having minimal effect on PGE₃ formation. The net result would be a reduction in osteoclast activity and serum NTx concentrations following the ALA diet.

We also examined the relationship between NTx and cytokines involved in bone remodeling, i.e. tumor necrosis factor-alpha (TNF α), IL-6, IL-4, and IL-1B [40, 41]. We previously reported that TNF- α was significantly lower when the ALA diet was

consumed relative to the AAD and LA diets [30]. In the present study, we showed that TNF- α levels were correlated with NTx levels across all of the diets. TNF- α promotes osteoclastic bone resorption and inhibits bone collagen synthesis in vitro [42], effects that may be mediated by PGE₂ [43]. In addition, TNF- α expression was enhanced by AA in human osteoblast cells, an effect that was attenuated by the n-3 fatty acid EPA [44].

Although TNF- α promotes osteoclastogenesis via an autocrine mechanism [45], systemic TNF- α also has been shown to stimulate bone resorption, increase the number of circulating preosteoclasts [46, 47], and elevate plasma calcium [43]. Furthermore, supplementation with flaxseed oil, which is rich in ALA, reduced systemic TNF- α by about 30% in humans [48], as well as in wild-type and IL-10 knockout mice [49], and increased bone mineral content in IL-10 knockout mice [49]. Systemic TNF- α therefore, may be an important marker of, and/or contributor to, bone resorptive mechanisms. Taken together, the present results are consistent with literature indicating that dietary ALA can reduce bone resorption possibly through reduced production of TNF- α .

In contrast to the effects of the diets on a marker of bone resorption, there were no effects on a marker of bone formation (BSAP) in the present study. Although others have reported that low dietary n-6/n-3 ratios increased BSAP in developing rats, the present results are consistent with other negative reports in adults. For instance, no change in plasma alkaline phosphatase activity was seen in adult rats maintained on high n-3 diets [50]. In addition, no change in BSAP occurred when supplements containing a mixture of n-6 and n-3 fatty acids were given to adult women [14, 15] over an extended period of time (≥ 12 mo), even though bone density increased in one of these trials [14]. The profile of effects reported here (reduced NTx, no change in BSAP) is similar to that

reported for a variety of factors affecting bone health including dietary protein and sodium [51, 52], nasal spray calcitonin (after 3 mo) [53], and calcium supplementation [54]. Such a profile suggests a reduction in bone turnover, and a shift in the balance of bone degradation/formation toward formation.

In the present study, most of the subjects were middle-aged men. While this population is generally overlooked in terms of bone health, the number of men who are afflicted with osteoporosis continues to grow [55]. Furthermore, recent epidemiologic data suggest that the effects of dietary fats on bone health may be particularly strong in men [6]. These reports as well as the present results indicate that bone health in men bears investigation, and that bone integrity in men, as well as in women, may benefit from manipulations of the dietary fatty acid profile.

In summary, the results of the present study indicate that incorporating walnuts and flaxseed into the diet as a means to increase ALA, and consequently decrease the n-6/n-3 ratio, reduces serum NTx and maintains levels of serum BSAP. The reductions in NTx were related to the amount of ALA each diet provided. Omega-3 fatty acids are known to have beneficial effects on the cardiovascular system, but few studies have examined their effects on human bone health. The present results suggest that incorporating plant sources of n-3 PUFA into the diet may provide health benefits not only to the cardiovascular system, but also to the skeletal system.

Acknowledgements:

The study was funded by the California Walnut Commission, Sacramento, CA. Partial support was provided by the General Clinical Research Center of The Pennsylvania State University (NIH grant M01RR10732).

Table 1: Subject Characteristics

	Men	Women	All
N	20	3	23
Age (y)	48.6 ± 1.6	58.3 ± 2.7	49.3 ± 1.6
BMI (kg/m ²)	28.0 ± 0.7	28.5 ± 2.4	28.1 ± 0.7
<i><u>Serum Lipids/Lipoproteins</u></i>			
Total Cholesterol (mmol/L)	5.74 ± 0.12	6.58 ± 0.28	5.85 ± 0.12
LDL-Cholesterol (mmol/L)	3.90 ± 0.11	4.53 ± 0.23	3.98 ± 0.11
HDL-Cholesterol (mmol/L)	1.12 ± 0.05	1.36 ± 0.11	1.16 ± 0.04
Triglycerides (mmol/L)	1.55 ± 0.18	1.51 ± 0.29	1.54 ± 0.16

Table 2: Nutritional composition of the three experimental diets (based on 2400 kcal/d); determined from chemical assay

Nutrients	AAD	LA Diet	ALA Diet
CHO*	49.8	46.8	46.3
Protein*	15.7	16.1	16.1
Total Fat*	34.5	37.1 †	37.6 †
SFA*	12.7	8.5 †	8.2 †
MUFA*	13.2	12.2	12.3
PUFA*	8.7	16.4 †	17.2 †
LA*	7.7	12.6 †	10.5 †¶
ALA*	0.8	3.6 †	6.5 †¶
LA/ALA (n-6/n-3)	9.5/1	3.5/1 †	1.6/1 †¶
Cholesterol** (mg/d)	310.8	303.5	305.0
Calcium** (mg)	975.3	1030.9	1016.8
Vitamin D** (µg/IU)	4.704/188.14 5	4.667/186.708	4.658/186.302

*Values are % energy; **Calculated using Nutritionist V; AAD: Average American Diet

LA Diet: A diet high in PUFA and LA; ALA Diet: A diet high in PUFA and ALA

CHO: Carbohydrate; SFA: Saturated fatty acids; MUFA: Monounsaturated fatty acids;

PUFA: Polyunsaturated fatty acids; LA: Linoleic acid; ALA: α -linolenic acid

†: P < 0.05 compared with AAD for assayed data

¶: P < 0.05 compared with LA Diet for assayed data

Table 3: Fatty acid profile (mol %) of serum total lipid in subjects on the three experimental diets (n=21)

	AAD	LA Diet	ALA Diet
SFA	34.7 ± 0.6	33.0 ± 0.5*	33.5 ± 0.5
MUFA	20.0 ± 0.6	17.0 ± 0.6‡	17.9 ± 0.6‡
PUFA	45.5 ± 0.7	50.1 ± 0.7‡	48.7 ± 0.7‡
<i>n-6 PUFA</i>	42.0 ± 0.6	44.9 ± 0.6‡	42.1 ± 0.6§
<i>LA</i>	33.3 ± 0.5	37.1 ± 0.5‡	34.6 ± 0.5*§
<i>AA</i>	8.2 ± 0.4	7.5 ± 0.4†	7.3 ± 0.4‡
n-3 PUFA	3.4 ± 0.3	5.2 ± 0.3‡	6.6 ± 0.3‡§
<i>ALA</i>	0.8 ± 0.2	2.1 ± 0.2‡	3.1 ± 0.2‡ζ
<i>EPA</i>	0.5 ± 0.1	0.7 ± 0.1‡	1.2 ± 0.1‡¶
<i>DPA</i>	0.6 ± 0.04	0.7 ± 0.04	0.7 ± 0.04‡¶
<i>DHA</i>	1.6 ± 0.1	1.7 ± 0.1	1.5 ± 0.1
SFA/UNSAT	0.53 ± 0.01	0.49 ± 0.01†	0.50 ± 0.01*
LA/ALA	49.6 ± 2.3	19.3 ± 2.3‡	12.4 ± 2.3‡¶
n-6/n-3	12.7 ± 0.5	9.0 ± 0.5‡	6.8 ± 0.5‡§

SFA: Saturated fatty acids; MUFA: Monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids; n-6: omega-6; LA: Linoleic acid; AA: Arachidonic acid; n-3: omega-3; ALA: α-linolenic acid; EPA: Eicosapentaenoic acid; DPA: Docosapentaenoic acid; DHA: Docosahexaenoic acid; UNSAT: total unsaturated fatty acids

*: P<0.05, †: P<0.01, ‡: P<0.001, compared with AAD

¶: P<0.05, ζ: P<0.01, §: P<0.001 compared with LA Diet

References

1. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G: **Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice.** *J Bone Miner Res* 2003, **18**(7):1206-1216.
2. Watkins BA, Li Y, Lippman HE, Feng S: **Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism.** *Prostaglandins Leukot Essent Fatty Acids* 2003, **68**(6):387-398.
3. Atkinson TG, Barker HJ, Meckling-Gill KA: **Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats.** *Lipids* 1997, **32**(3):293-302.
4. Kokkinos PP, Shaye R, Alam BS, Alam SQ: **Dietary lipids, prostaglandin E2 levels, and tooth movement in alveolar bone of rats.** *Calcif Tissue Int* 1993, **53**(5):333-337.
5. Wohl GR, Loehrke L, Watkins BA, Zernicke RF: **Effects of high-fat diet on mature bone mineral content, structure, and mechanical properties.** *Calcif Tissue Int* 1998, **63**(1):74-79.
6. Corwin RL, Hartman TJ, Maczuga SA, Graubard BI: **Dietary saturated fat intake is inversely associated with bone density in humans: analysis of NHANES III.** *J Nutr* 2006, **136**(1):159-165.
7. Haag M, Magada ON, Claassen N, Bohmer LH, Kruger MC: **Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption.** *Prostaglandins Leukot Essent Fatty Acids* 2003, **68**(6):423-429.
8. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF: **Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats.** *J Nutr* 2000, **130**(9):2274-2284.
9. Watkins BA, Li Y, Lippman HE, Seifert MF: **Omega-3 polyunsaturated fatty acids and skeletal health.** *Exp Biol Med (Maywood)* 2001, **226**(6):485-497.
10. Parhami F: **Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor?** *Prostaglandins Leukot Essent Fatty Acids* 2003, **68**(6):373-378.
11. Corwin RL: **Effects of dietary fats on bone health in advanced age.** *Prostaglandins Leukot Essent Fatty Acids* 2003, **68**(6):379-386.
12. Weiss LA, Barrett-Connor E, von Muhlen D: **Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study.** *Am J Clin Nutr* 2005, **81**(4):934-938.
13. Terano T: **Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis.** *World Rev Nutr Diet* 2001, **88**:141-147.
14. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH: **Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis.** *Aging (Milano)* 1998, **10**(5):385-394.
15. Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW: **Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy**

- pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone.** *Br J Nutr* 2000, **83**(6):629-635.
16. Van Papendorp D, Coetzer, H, Kruger, MC: **Biochemical profile of osteoporotic patients on essential fatty acid supplementation.** *Nutr Res* 1995, **15**(3):325-334.
 17. Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B: **The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial.** *J Clin Endocrinol Metab* 2005, **90**(3):1390-1397.
 18. Trebble TM, Stroud MA, Wootton SA, Calder PC, Fine DR, Mullee MA, Moniz C, Arden NK: **High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial.** *Br J Nutr* 2005, **94**(2):253-261.
 19. Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM: **Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women.** *J Nutr* 2004, **134**(11):2991-2997.
 20. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR: **Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?** *Endocrine* 2004, **23**(1):1-10.
 21. Mechanick JI, Liu K, Nierman DM, Stein A: **Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.** *J Spinal Cord Med* 2006, **29**(4):406-412.
 22. Kim H, Iwasaki K, Miyake T, Shiozawa T, Nozaki S, Yajima K: **Changes in bone turnover markers during 14-day 6 degrees head-down bed rest.** *J Bone Miner Metab* 2003, **21**(5):311-315.
 23. National Academy of Sciences and Institutes of Medicine: **Dietary Reference Intakes: Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.** In. Washington, DC: National Academies Press; 2002.
 24. The National Academies Press: **Dietary fats: total fat and fatty acids.** In: *Dietary Reference Intakes - Energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids.* Washington, DC; 2002: 8-1 - 8-97.
 25. Clemens JD, Herrick MV, Singer FR, Eyre DR: **Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.** *Clin Chem* 1997, **43**(11):2058-2063.
 26. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, Fressland K, Chesnut C, 3rd: **Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women.** *J Bone Miner Res* 2000, **15**(3):594-598.
 27. Takahashi M, Kawana K, Nagano A: **Biological variability of biochemical markers of bone turnover in healthy women.** *Endocr Res* 2002, **28**(3):257-264.
 28. Garner P, Delmas PD: **Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.** *The Journal of clinical endocrinology & metabolism* 1993, **77**(4):1046-1053.

29. Zhao G, Etherton TD, Martin KR, Vanden Heuvel JP, Gillies PJ, West SG, Kris-Etherton PM: **Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells.** *Biochem Biophys Res Commun* 2005, **336**(3):909-917.
30. Zhao G, Etherton, TD., Martin, KR., Gillies, PJ., West, SG., Kris-Etherton PM.,: **Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects.** *Am J Clin Nutr* submitted 2006.
31. Feldman EB: **The scientific evidence for a beneficial health relationship between walnuts and coronary heart disease.** *J Nutr* 2002, **132**(5):1062S-1101S.
32. Bloedon LT, Szapary PO: **Flaxseed and cardiovascular risk.** *Nutr Rev* 2004, **62**(1):18-27.
33. Simopoulos AP: **The importance of the ratio of omega-6/omega-3 essential fatty acids.** *Biomed Pharmacother* 2002, **56**(8):365-379.
34. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP: **Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses.** *J Lipid Res* 2005, **46**(7):1474-1483.
35. Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ: **Long-chain conversion of [¹³C]linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men.** *J Lipid Res* 2005, **46**(2):269-280.
36. Gerster H: **Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)?** *Int J Vitam Nutr Res* 1998, **68**(3):159-173.
37. Chesnut CH, 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC, Jr., Notelovitz M, Rosen C, Cain DF, Flessland KA *et al*: **Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.** *Am J Med* 1997, **102**(1):29-37.
38. Greenspan SL, Rosen HN, Parker RA: **Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.** *J Clin Endocrinol Metab* 2000, **85**(10):3537-3540.
39. Raisz LG, Alander CB, Simmons HA: **Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture.** *Prostaglandins* 1989, **37**(5):615-625.
40. Tanaka Y, Nakayamada S, Okada Y: **Osteoblasts and osteoclasts in bone remodeling and inflammation.** *Curr Drug Targets Inflamm Allergy* 2005, **4**(3):325-328.
41. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y: **IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.** *Cytokine Growth Factor Rev* 2004, **15**(1):49-60.
42. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR: **Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.** *Nature* 1986, **319**(6053):516-518.

43. Tashjian AH, Jr., Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L: **Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism.** *Endocrinology* 1987, **120**(5):2029-2036.
44. Priante G, Bordin L, Musacchio E, Clari G, Baggio B: **Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid.** *Clin Sci (Lond)* 2002, **102**(4):403-409.
45. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z: **Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.** *J Cell Biochem* 2001, **83**(1):70-83.
46. Konig A, Muhlbauer RC, Fleisch H: **Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H]tetracycline excretion from prelabeled mice.** *J Bone Miner Res* 1988, **3**(6):621-627.
47. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L: **Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.** *Arthritis Rheum* 2004, **50**(1):265-276.
48. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ: **The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil.** *Am J Clin Nutr* 1996, **63**(1):116-122.
49. Cohen SL, Moore AM, Ward WE: **Flaxseed oil and inflammation-associated bone abnormalities in interleukin-10 knockout mice.** *J Nutr Biochem* 2005, **16**(6):368-374.
50. Yamada Y, Fushimi H, Inoue T, Matsuyama Y, Kameyama M, Minami T, Okazaki Y, Noguchi Y, Kasama T: **Effect of eicosapentaenoic acid and docosahexaenoic acid on diabetic osteopenia.** *Diabetes Res Clin Pract* 1995, **30**(1):37-42.
51. Harrington M, Bennett T, Jakobsen J, Ovesen L, Brot C, Flynn A, Cashman KD: **The effect of a high-protein, high-sodium diet on calcium and bone metabolism in postmenopausal women and its interaction with vitamin D receptor genotype.** *Br J Nutr* 2004, **91**(1):41-51.
52. Kerstetter JE, Mitnick ME, Gundberg CM, Caseria DM, Ellison AF, Carpenter TO, Insogna KL: **Changes in bone turnover in young women consuming different levels of dietary protein.** *J Clin Endocrinol Metab* 1999, **84**(3):1052-1055.
53. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E: **A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.** *J Bone Miner Res* 2002, **17**(3):521-527.
54. Kenny AM, Prestwood KM, Biskup B, Robbins B, Zayas E, Kleppinger A, Burleson JA, Raisz LG: **Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women.** *Osteoporos Int* 2004, **15**(4):290-294.

55. Adler RA: **Epidemiology and pathophysiology of osteoporosis in men.** *Curr Osteoporos Rep* 2006, **4**(3):110-115.




Figure 1: NTx levels when diets differing in fatty acid composition were consumed. ^a $p < 0.05$ when compared to AAD. Vertical bars represent the standard errors of the means.

